Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth Paul; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak
(Future Medicine, 2022)
PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...